Methylprednisolone and JAK inhibitor for severe skin reaction
Treatments studied
Part of Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests a combination of a steroid (methylprednisolone) and a JAK inhibitor to treat toxic epidermal necrolysis, a severe skin reaction. The goal is to see if adding the JAK inhibitor helps improve outcomes and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be diagnosed with Stevens-Johnson syndrome or toxic epidermal necrolysis by a doctor.
- Your liver, kidney, and blood tests must be in acceptable ranges.
- You must not be pregnant or breastfeeding.
- You must not have a history of severe infections, tuberculosis, or certain other conditions.
- You must be willing to sign a consent form and attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug called daratumumab can help people with a severe skin reaction (SJS/TEN) caused by a medication. It aims to stop the reaction from getting worse.
This early-phase trial tests stem-cell treatment to help people with severe skin reactions called SJS-TEN. It may reduce ongoing skin damage and help recovery when treatment is started soon after symptoms begin.
This trial tests whether a JAK inhibitor (a type of drug) can help patients with solid cancers who developed severe skin rashes from immunotherapy drugs and didn't get better with steroids. The goal is to find a new treatment option for this painful side effect.
This study tests a JAK inhibitor pill for people with severe skin rashes caused by immunotherapy drugs like Keytruda or Opdivo. It aims to help control the rash and allow you to keep benefiting from your cancer treatment.
This trial tests whether a new class of drugs called JAK inhibitors (which block inflammation signals) is better than a standard treatment (calcineurin inhibitors) for people with lung scarring (interstitial lung disease) caused by Anti-Synthetase Syndrome. It is for people who have not yet taken any immune-suppressing medications for this condition.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
Hear when a new Toxic Epidermal Necrolysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.